Novartis has not decided what to do with its Sandoz generics unit after announcing a strategic review of the business last year, its chief executive said on Monday.. | January 10, 2022
Novartis s potential sale of its Sandoz generic drug business is attracting interest from possible buyers, Chief Executive Vas Narasimhan said in an interview to be published on Friday.. | December 10, 2021
Roche s $20.7 billion move to buy back nearly a third of its voting stock from fellow Swiss drugmaker Novartis will give it more strategic flexibility, Chairman Christoph Franz said in an. | November 6, 2021
Novartis has agreed to
expand its fill-and-finish support for the Pfizer/BioNTech
COVID-19 vaccine by using manufacturing
facilities Ljubljana, Slovenia, to fill at least 24 million
doses in 2022, the. | October 21, 2021